|
|
|
|
|
|
|
MESSAGE _ENGLISH VERSION_
|
|
|
|
|
|
|
|
|
Receipt of a Significant Purchase Order
The Management Board of Selvita S.A., with its registered office in
Kraków _the "Issuer", the "Company"_, with reference to current report
No. 24/2025 dated September 23, 2025, announces that on April 2, 2026
the Issuer received another order _the "Order"_ from a biopharmaceutical
company headquartered in Europe _the "Client"_, under an agreement
concluded with the Client in 2022.
The Order extends the cooperation with the Client for a further 11
months, i.e. until February 28, 2027, and covers the provision of
services including the design and synthesis of new chemical compounds
and their evaluation in a broad panel of in vitro tests, aimed at
characterizing their biological activity and ADME properties
_Absorption, Distribution, Metabolism, Excretion_, as well as the
delivery of high quality data supporting decision making in subsequent
stages of the Client's drug discovery project.
The value of the Order amounts to EUR 1,325,370 _i.e. PLN 5,682,391_.
The estimated total value of services provided to the Client throughout
2026, taking into account the Order, will amount to EUR 2,311,755 _i.e.
PLN 9,911,421_.
Due to the total value of cooperation between the Client and the Issuer
in 2026 and resulting from the received Order exceeds EUR 2,000,000, as
well as the strategic nature of the continued cooperation in the area of
integrated drug discovery, the Issuer's Management Board considers the
received Order to be significant.
The currency conversions in this report were made based on the average
exchange rate of the National Bank of Poland as of April 1, 2026,
amounting to EUR 1 = PLN 4.2874.
Disclaimer: This English language translation has been prepared solely
for the convenience of English-speaking readers. Despite all the efforts
devoted to this translation, certain discrepancies, omissions, or
approximations may exist. In case of any differences between the Polish
and the English versions, the Polish version shall prevail. Selvita
S.A., its representatives, and employees decline all responsibility in
this regard.
|
|
|
|
|
|
|
|
RB: Otrzymanie istotnego zlecenia / Receipt of a Significant Purchase Order
